

Business Stream Products Medical Products



TÜVRheinland®
LGA

Precisely Right.

TÜV Rheinland LGA Products GmbH * 51105 Köln * Am Grauen Stein 29 * Germany

DuPont de Nemours
(Luxembourg) S.à.r.l.
Rue Général Patton
L-2984 Luxembourg

Your correspondence
Dr. Katsebn Kluge

Tel. +49 221/806-2656
Fax +49 221/806-1601
Karsten.Kluge@de.tuv.com

Customer Service Centre
for Products

Tel. +49 9 11 6 55-5225
Mail service@de.tuv.com

Köln, 06 July 2012

DuPont Tyvek Packaging Transition

To whom it may concern

DuPont Medical and Pharmaceutical Packaging will be transitioning Tyvek® 1073B and 1059B styles for medical packaging applications to manufacturing lines using the latest Tyvek® manufacturing technology.

In preparation of this transition, DuPont presented to TÜV Rheinland LGA Products GmbH, a set of limited studies designed to demonstrate the functional equivalence of Tyvek® non-wovens manufactured under an upgraded flash-spinning process to Tyvek® products manufactured by the present process. The studies are detailed in a document entitled "*Addendum to the Protocol for Transition of the Medical Device Industry to Tyvek® Manufactured Using an Upgraded Spinning Process*" accepted by the US FDA on September 15, 2011. TÜV Rheinland LGA Products GmbH has reviewed and examined the study design and considers the protocol to be an applicable set of tests in order to demonstrate the functional equivalence.

Upon successful completion of the proposed tests and demonstration of satisfactory evidence that the performance (process capability, sterility, package integrity, etc.) of Tyvek® products from the upgraded process is functionally equivalent to existing Tyvek® products, DuPont will document and publicise the approved study conclusions including the range of sterilisation processes and conditions covered.

In accordance with their specific change assessment process, risk management process as well as in accordance with sterilisation standards, manufacturers will have to review the change in Tyvek® and have documented records of their change review including review of risks, rationale for accepting the protocol conclusions for their application or identification of further testing required. Such records will need to be included in the respective medical device design files.

It is expected that the Legal Manufacturers who hold CE Certification for Class Is, IIa and IIb will assess DuPont information within their specific change control process in accordance with sterilisation standards and implement the change through their Quality System, which will be reviewed at the next scheduled Notified Body Audit.

TÜV Rheinland
LGA Products GmbH

Am Grauen Stein
51105 Cologne
Germany

Headquarter

TÜV Rheinland
LGA Products GmbH

Tillystraße 2
90431 Nuremberg
Germany

Phone +49 911 655 5225
Fax +49 911 655 5226
service@de.tuv.com
www.tuv.com/safety

Board of Management

Dipl.-Ing. Jörg Mähler,
Speaker

Dipl.-Kfm.
Dr. Jörg Schlösser

Nuremberg HRB 26013

VAT No.: DE811835490

...

For Legal Manufacturers who hold CE Certification for Class III devices it is expected that the impact of the change will be assessed, the applicability of DuPont's information on the product, rationale for accepting the protocol conclusions for their application and/or identification of further testing required. This should be submitted to the relevant Notified Body under a significant change notification. It is expected that consideration will be given to the work carried out by DuPont by Notified Bodies in relation to the general aspects of the material equivalence when reviewing the significant change notification.

Sincerely

i.V.



Dr. Karsten Kluge

i.V.



Dr. Gero Viola